trending Market Intelligence /marketintelligence/en/news-insights/trending/CePvKcaZugrGHCaZUzHRSg2 content esgSubNav
In This List

Cadila secures US FDA approval for epilepsy drug

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Cadila secures US FDA approval for epilepsy drug

Cadila Healthcare Ltd., under the aegis of Zydus Cadila, secured the U.S. Food and Drug Administration approval for Felbamate tablets.

The drug is used for the treatment of seizures in people with epilepsy.